TEXT OF STORY
Doug Krizner: The controversial diabetes drug Avandia has been a problem for its maker, GlaxoSmithKline. Research has concluded the drug carries the risk of heart attack. Now, the British pharmaceutical giant may have to cut its sales force in response. From London, Stephen Beard reports.
Stephen Beard: Glaxo is still insisting that what was once its second-best selling drug is safe. But the company is nevertheless revising its marketing plans. One analyst quoted in the British press suggests that Glaxo could cut its Avandia sales force in the U.S. by 5 percent.
Sales of the drug have slumped, and its future looks uncertain. A study by a leading cardiologist at the Cleveland Clinic has raised serious concerns. He warned that patients on Avandia were much more likely to have a heart attack or stroke. Another study by German researchers came to the same conclusion.
The U.S. Food and Drug Administration is considering the matter. Some of the FDA’s advisors have already recommended that Avandia carry a health warning.
In London, this is Stephen Beard for Marketplace.
We’re here to help you navigate this changed world and economy.
Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.
In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.
Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.